Chiesi Group unveiled a $486 million collaboration with Gossamer Bio on Monday. The deal aims to develop seralutinib for pulmonary arterial hypertension.
Under the deal, Gossamer will lead the global development of seralutinib in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug is a PDGFRα/β, CSF1R, and c-KIT inhibitor that delivers a dry powder via an inhaler.
San Diego-based biotech Gossamer will receive $160 million in development reimbursement and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones. The biotech will also take the lead on commercialization and booking sales for the drug in PAH and PH-ILD in the U.S., with both companies providing 50% of the commercial efforts.
Through this partnership, both companies are poised to capitalize on emerging opportunities in the field of respiratory medicine. Furthermore, the collaboration between Gossamer Bio and Chiesi Group underscores their shared commitment to advancing medical innovation.
Together, they will harness the power of collaboration to drive progress in the treatment of lung conditions. This collaboration heralds a new era of innovation, offering hope to individuals grappling with lung conditions. Moreover, it paves the way for a brighter future with promising breakthroughs.
read more
image source
